The PH-ILD market is set to expand steadily through the forecast period, driven by the anticipated entry of advanced therapies, improved clinical management, and growing recognition of the disease. As diagnostic practices continue to improve, the treatable patient pool is expected to widen, fueling demand for both existing standard-of-care therapies and an emerging pipeline of next-generation inhaled and oral modalities.
DelveInsight’s “Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) – Market Insights, Epidemiology and Market Forecast – 2036” report offers an in-depth understanding of PH-ILD, historical and forecasted epidemiology, as well as the PH-ILD market trends in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.
To know in detail about the PH-ILD market outlook, drug uptake, treatment scenario, and epidemiology trends, Click here: PH-ILD Market Forecast
Some of the Key Facts of the PH-ILD Market Report:
- The PH-ILD market across the 7MM was valued at approximately USD 3 billion in 2025 and is projected to grow at a CAGR of 3.9% through 2036.
- The United States accounted for the largest PH-ILD market size among the 7MM, valued at approximately USD 2,500 million in 2025.
- EU4 and the UK combined represented a market size of approximately USD 500 million in 2025, driven by increasing adoption of specialized inhaled therapies.
- Japan accounted for a market size of approximately USD 300 million in 2025.
- Treprostinil (TYVASO/TYVASO DPI/TREPROST), from United Therapeutics, generated over ~USD 1,100 million across the 7MM in 2025.
- As of 2025, the total diagnosed prevalent population of PH-ILD across the 7MM is estimated at nearly 182,000, while the broader diagnosed prevalent population of ILD in the 7MM exceeded 1 million cases.
- In 2025, the United States accounted for approximately 83,000 diagnosed prevalent cases of PH-ILD, the largest patient base among the 7MM.
- In 2025, EU4 and the UK together contributed approximately 70,000 cases, with the United Kingdom representing the largest individual European segment at nearly 18,000 cases.
- Japan accounted for approximately 29,000 diagnosed prevalent cases of PH-ILD in 2025.
- Gender-specific analysis in the United States for 2025 shows a slightly higher prevalence in males (~43,000 cases) than females (~40,000 cases).
- In May 2025, YUTREPIA (treprostinil inhalation powder), developed by Liquidia Corporation, received full FDA approval for improving exercise capacity in adults with PAH and PH-ILD — the first dry powder prostacyclin therapy enabled by Liquidia’s PRINT technology.
- The annual treatment cost of YUTREPIA in the United States is approximately USD 300,000.
- Key PH-ILD Companies: Liquidia Corporation, United Therapeutics, Pharmosa BioPharm, Halo Biosciences, Roivant Sciences/Pulmovant, Insmed, and others.
- Key PH-ILD Therapies: Treprostinil (YUTREPIA), Treprostinil (TYVASO/TYVASO DPI/TREPROST), Treprostinil liposomal (L606), Treprostinil Palmitil Inhalation Powder (TPIP), H1614 (HB-1614), and others.
PH-ILD Overview
PH-ILD refers to a wide range of lung conditions involving scarring or inflammation of the interstitium — the thin tissue layer between the air sacs and nearby blood vessels that maintains alveolar structure and enables oxygen transfer into the bloodstream. Chronic smoking and long-term exposure to environmental or occupational toxins can damage lung tissue, contributing to inflammation and fibrosis that elevate pulmonary artery pressure.
Diagnosing PH-ILD requires a combination of noninvasive and invasive methods. Since ILD and PH share many overlapping signs, healthcare providers rely on tools such as pulmonary function tests, the 6-minute walk distance (6MWD), echocardiography, and chest imaging, while Right Heart Catheterization (RHC) remains the most accurate and conclusive diagnostic method.
Get a Free sample for the PH-ILD Market Report: https://www.delveinsight.com/report-store/pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild-market
PH-ILD Epidemiology
The PH-ILD epidemiology section provides historical, current, and forecasted trends in the seven major markets (7MM) from 2022 to 2036. It helps recognize the causes of current and forecasted trends by exploring published studies and the views of key opinion leaders, and provides a detailed analysis of the diagnosed patient pool.
PH-ILD Epidemiology Segmentation:
- Diagnosed Prevalent Cases of ILD
- Type-specific Diagnosed Prevalent Cases of ILD
- Type-specific Diagnosed Prevalent Cases of PH-ILD
- Total Diagnosed Prevalent Cases of PH-ILD
- Gender-specific Diagnosed Prevalent Cases of PH-ILD
Download the report to understand which factors are driving PH-ILD epidemiology trends @ PH-ILD Epidemiology Forecast
PH-ILD Market
The dynamics of the PH-ILD market are anticipated to shift in the coming years owing to high unmet clinical need, increasing disease recognition, and the progressive nature of the cardiopulmonary impairment associated with the condition. While no curative therapies currently exist, growing adoption of supportive care, oxygen therapy, and targeted pulmonary vasodilators — alongside advancements in understanding disease pathophysiology — is expected to support market growth and improve long-term patient management outcomes.
“Currently, the landscape is anchored by approved inhaled therapies like treprostinil (TYVASO/TYVASO DPI/TREPROST) and the emergence of treprostinil (YUTREPIA), with the transition toward next-generation therapies such as treprostinil liposomal (L606) and treprostinil palmitil (TPIP) representing a significant leap in precision delivery.”
PH-ILD Therapies and Key Companies
- Treprostinil (YUTREPIA): Liquidia Corporation — a dry powder inhalation formulation of treprostinil sodium delivered via a single-use, handheld inhaler; received full FDA approval in May 2025 for improving exercise capacity in adults with PAH and PH-ILD.
- Treprostinil (TYVASO/TYVASO DPI/TREPROST): United Therapeutics — inhalation solution and dry powder inhaler approved for both PAH and PH-ILD, marketed in the US since 2022 and in Japan since 2024.
- Treprostinil liposomal (L606): Pharmosa BioPharm/Liquidia Corporation — a liposomal formulation (110–140 nm particles) engineered for sustained pulmonary release; currently in Phase III with anticipated US launch in 2030.
- Treprostinil Palmitil Inhalation Powder (TPIP): Insmed — a late-stage oral inhalation pipeline candidate.
- Mosliciguat: Roivant Sciences/Pulmovant — a Phase II guanylate cyclase stimulant delivered via inhalation.
- H1614 (HB-1614): Halo Biosciences — a Phase II oral hyaluronan-synthesis inhibitor.
To know more about PH-ILD treatment, visit @ PH-ILD Medications
PH-ILD Market Drivers
- Increasing Recognition of the Disease and Improved Diagnostic Practices
- Anticipated Entry of Advanced and Next-Generation Inhaled/Oral Therapies
- Expansion of Approved Indications (e.g., YUTREPIA’s full FDA approval)
- Growing Adoption of Targeted Pulmonary Vasodilators
- Advancements in Disease Pathophysiology Understanding
- Robust Late-Stage Pipeline (L606, TPIP, Mosliciguat, H1614)
PH-ILD Market Barriers
- Delayed Diagnosis Due to Symptom Overlap with ILD
- Reliance on Invasive Right Heart Catheterization for Definitive Diagnosis
- Lack of Non-Invasive Biomarkers and Standardized Diagnostic Pathways
- Scarcity of Specifically Approved Therapies, Driving Off-Label PAH Drug Use
- High Annual Treatment Costs (e.g., ~USD 300,000 for YUTREPIA)
- Persistent Therapeutic Gaps Despite Available Inhaled Options
PH-ILD Competitive Landscape
The PH-ILD competitive landscape is currently anchored by two approved inhaled prostacyclin therapies: United Therapeutics’ Treprostinil (TYVASO/TYVASO DPI/TREPROST), the first inhaled treprostinil therapy approved specifically for PH-ILD, and Liquidia Corporation’s Treprostinil (YUTREPIA), the first dry powder prostacyclin therapy enabled by PRINT technology. Despite these options, off-label use of PAH-approved medications remains common, prescribed to nearly half of PH-ILD patients according to clinician-reported data, underscoring persistent therapeutic gaps. The emerging pipeline is led by Pharmosa BioPharm/Liquidia’s Phase III liposomal treprostinil (L606), alongside Insmed’s TPIP, Roivant Sciences/Pulmovant’s mosliciguat, and Halo Biosciences’ H1614 (HB-1614) — all aiming to optimize drug delivery, extend dosing intervals, and expand into inadequately served patient populations.
Scope of the PH-ILD Market Report
- Study Period: 2022–2036
- Coverage: 7MM
- Key PH-ILD Companies: Liquidia Corporation, United Therapeutics, Pharmosa BioPharm, Halo Biosciences, Roivant Sciences/Pulmovant, Insmed, and others
- Key PH-ILD Therapies: Treprostinil (YUTREPIA), Treprostinil (TYVASO/TYVASO DPI/TREPROST), Treprostinil liposomal (L606), Treprostinil Palmitil Inhalation Powder (TPIP), H1614 (HB-1614), and others
- PH-ILD Therapeutic Assessment: Current marketed and emerging therapies
- PH-ILD Market Dynamics: Market drivers and market barriers
- Competitive Intelligence Analysis: SWOT analysis, Attribute analysis, Cost assumptions and pricing analogues, KOL views
- PH-ILD Unmet Needs, KOL’s Views, Analyst’s Views, Market Access and Reimbursement
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefit market analysis to accelerate business growth and overcome challenges with a practical approach.
Contact Us
Kanishk
